Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting
Mainz Biomed (NASDAQ:MYNZ) will present groundbreaking clinical data from their eAArly DETECT study at the World Endoscopy Organization's CRC Screening Committee Meeting on October 3rd, 2025 in Berlin.
Dr. Lena Krammes will showcase the company's RNA-based diagnostic test results, which demonstrated remarkable efficacy with 97% sensitivity and specificity for colorectal cancer detection, 82% sensitivity for advanced adenomas, and 100% detection rate for advanced adenomas with high-grade dysplasia.
The presentation, titled "From Detection to Prevention," will highlight the potential of stool RNA testing in both early cancer detection and prevention through identification of high-risk lesions.
Mainz Biomed (NASDAQ:MYNZ) presenterà dati clinici rivoluzionari dal loro studio eAArly DETECT durante la riunione del CRC Screening Committee dell'Organizzazione Endoscopica Mondiale (World Endoscopy Organization) a Berlino il 3 ottobre 2025.
La Dott.ssa Lena Krammes presenterà i risultati del test diagnostico basato su RNA dell'azienda, che hanno dimostrato un'efficacia notevole con 97% sensibilità e specificità per il rilevamento del cancro colorettale, 82% sensibilità per gli adenomi avanzati, e 100% tasso di rilevazione per adenomi avanzati con displasia ad alto grado.
La presentazione, intitolata "From Detection to Prevention", evidenzierà il potenziale dei test RNA nelle feci sia per la rilevazione precoce del cancro sia per la prevenzione mediante l'identificazione di lesioni ad alto rischio.
Mainz Biomed (NASDAQ:MYNZ) presentará datos clínicos innovadores de su estudio eAArly DETECT en la Reunión del Comité de Detección CRC de la World Endoscopy Organization el 3 de octubre de 2025 en Berlín.
La Dra. Lena Krammes mostrará los resultados de la prueba diagnóstica basada en ARN de la empresa, que demostró una eficacia notable con 97% de sensibilidad y especificidad para la detección del cáncer colorrectal, 82% de sensibilidad para adenomas avanzados, y 100% tasa de detección para adenomas avanzados con displasia de alto grado.
La presentación, titulada "From Detection to Prevention", destacará el potencial de las pruebas de ARN en heces para la detección temprana del cáncer y la prevención mediante la identificación de lesiones de alto riesgo.
Mainz Biomed (NASDAQ:MYNZ)는 World Endoscopy Organization의 CRC Screening Committee 회의에서 2025년 10월 3일 베를린에서 eAArly DETECT 연구의 획기적인 임상 데이터를 발표할 예정입니다.
Lena Krammes 박사는 회사의 RNA 기반 진단 테스트 결과를 선보일 것이며, 이는 대장암 탐지에 대해 97% 민감도 및 특이도, 진행된 선종에 대해 82% 민감도, 그리고 고등 정도의 이형성증을 가진 진행된 선종에 대해 100% 탐지률을 보여주었습니다.
발표 제목인 "From Detection to Prevention"은 배설물 RNA 검사의 초기 암 탐지와 고위험 병변 식별을 통한 예방 가능성을 강조합니다.
Mainz Biomed (NASDAQ:MYNZ) présentera des données cliniques révolutionnaires de son étude eAArly DETECT lors de la réunion du CRC Screening Committee de la World Endoscopy Organization à Berlin le 3 octobre 2025.
Le Dr Lena Krammes exposera les résultats du test diagnostique basé sur l'ARN de l'entreprise, qui ont démontré une efficacité remarquable avec 97% de sensibilité et de spécificité pour la détection du cancer colorectal, 82% de sensibilité pour les adénomes avancés, et 100% de taux de détection pour les adénomes avancés avec dysplasie de haut grade.
La présentation, intitulée « From Detection to Prevention », mettra en lumière le potentiel des tests d'ARN dans les selles, tant pour la détection précoce du cancer que pour la prévention par l'identification de lésions à haut risque.
Mainz Biomed (NASDAQ:MYNZ) wird bahnbrechende klinische Daten aus ihrer eAArly DETECT-Studie auf der Sitzung des CRC-Screening-Ausschusses der World Endoscopy Organization in Berlin am 3. Oktober 2025 präsentieren.
Dr. Lena Krammes wird die RNA-basierte Diagnostik des Unternehmens vorstellen, die eine bemerkenswerte Wirksamkeit gezeigt hat mit 97% Empfindlichkeit und Spezifität für die Erkennung von kolorektalem Krebs, 82% Empfindlichkeit für fortgeschrittene Adenome und 100% Nachweisrate für fortgeschrittene Adenome mit hochgradiger Dysplasie.
Die Präsentation mit dem Titel "From Detection to Prevention" wird das Potenzial von Stuhl-RNA-Tests sowohl für die Früherkennung als auch für die Prävention durch Identifizierung von Hochrisikolesionen hervorheben.
Mainz Biomed (NASDAQ:MYNZ) ستعرض بيانات سريرية رائدة من دراستهم eAArly DETECT خلال اجتماع لجنة فحص CRC التابعة لمنظمة التنظير العالمية في برلين في 3 أكتوبر 2025.
ستعرض الدكتورة لينا كرامس نتائج الاختبار التشخيصي القائم على RNA للشركة، والتي أظهرت فعالية ملحوظة مع معدل حساسية ونوعية قدره 97% لاكتشاف سرطان القولون والمستقيم، و82% حساسية لأورام غدية متقدمة، ومعدل اكتشاف 100% للأورام الغدية المتقدمة ذات خلل التنسج عالي الدرجة.
سيُبرز العرض، بعنوان "From Detection to Prevention"، إمكانات فحص RNA في البراز في كل من الكشف المبكر عن السرطان والوقاية من خلال تحديد lesions عالية الخطر.
Mainz Biomed（NASDAQ:MYNZ） 将在柏林举行的世界内镜组织（World Endoscopy Organization）CRC筛查委员会会议上公布其 eAArly DETECT 研究的突破性临床数据，时间为2025年10月3日。
Lena Krammes 博士将展示公司的基于RNA的诊断测试结果，该结果在大肠癌检测方面显示出显著的有效性，对结直肠癌检测的敏感性和特异性均为97%，进展期腺瘤的敏感性为82%，以及对高等级化生的进展性腺瘤的检测率为100%。
题为“From Detection to Prevention”的报告将强调粪便RNA检测在早期癌症检测与通过识别高风险病变进行预防方面的潜力。
- None.
- None.
BERKELEY, Calif. and MAINZ, Germany, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in the upcoming Colorectal Cancer (CRC) Screening Committee Plenary Meeting and Expert Working Group (EWG) Sessions hosted by the World Endoscopy Organization (WEO), taking place on October 3rd, 2025, in Berlin, Germany.
This high-level gathering brings together global leaders in colorectal cancer screening to evaluate emerging technologies, exchange scientific insights, and help shape future strategies for early detection and prevention of CRC. As part of the session titled "Evaluation of New Tests", Dr. Lena Krammes, Senior Scientist at Mainz Biomed, will present findings from the Company’s ongoing work in RNA-based diagnostics.
Dr. Krammes’ talk, titled “From Detection to Prevention – Early Evidence from RNA-based Screening Test for Precancerous Lesions Compared to Different FIT Cut-offs,” will showcase clinical data from the eAArly DETECT study, generated in 2024 highlighting the potential of stool RNA testing to identify both colorectal cancer and precancerous lesions. Key findings include:
97% sensitivity and97% specificity for detecting colorectal cancer82% sensitivity for advanced adenomas100% detection of advanced adenomas with high-grade dysplasia
These results underline the potential for RNA-based testing to play a significant role not only in early detection of CRC, but also in prevention, by identifying high-risk lesions before cancer develops.
Mainz Biomed’s participation reflects its commitment to contributing to the global effort to improve CRC screening outcomes. The World Endoscopy Organization is a global non-profit organization dedicated to promoting high-quality endoscopy and the advancement of digestive health. Through its Colorectal Cancer Screening Committee, WEO works to promote CRC screening activities worldwide and support the implementation of screening programs, including fecal immunochemical tests (FIT), stool-based tests, and endoscopic procedures.
“We are honored to take part in this prestigious meeting,” said Guido Baechler, CEO of Mainz Biomed. “The invitation to join these expert discussions reinforces our belief that we are making important contributions toward developing effective, next-generation screening tools that can prevent colorectal cancer before it starts.”
Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information
Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook
About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe. The Company is currently running its eAArly DETECT 2 clinical study in preparation for its pivotal FDA study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in blood and stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.
For media inquiries
MC Services AG
Maximilian Schur / Simone Neeten
+49 211 529252 20
mainzbiomed@mc-services.eu
For investor inquiries, please contact ir@mainzbiomed.com
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on March 31, 2025. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
FAQ
What clinical results will Mainz Biomed (MYNZ) present at the WEO CRC Screening Committee Meeting?
When and where will Mainz Biomed (MYNZ) present their colorectal cancer screening data?
Who will present Mainz Biomed's RNA-based diagnostic findings at the WEO meeting?
What is the significance of Mainz Biomed's RNA-based testing for colorectal cancer screening?
